GSK Calls For Preemption Ruling In Zofran Birth Defect MDL
GlaxoSmithKline has renewed its bid to end multidistrict litigation in Massachusetts federal court over claims it didn't warn customers about alleged birth defects resulting from its anti-nausea medication, saying a recent...To view the full article, register now.
Already a subscriber? Click here to view full article